Monday 19 October 2026
Export BLSM’s income statement to Excel — free account
BlossomHill Therapeutics, Inc.
BLSM
Insiders bought in the last twelve months.
13.94
1.04
−6.94%
Follow BLSM
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+1 more quarter Free account |
— | 8.97 | 7.40 | 5.42 |
Net Debt/EBITDA |
0.00 | 0.00 | 5.28 | 3.89 | |
Debt/Assets |
— | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.69 | — | 1.00 | 0.98 | |
Capex/Depreciation |
(5.83) | — | (0.10) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
— | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Free Cash Flow per Share |
(4.05) | — | (8.12) | (8.56) | |
Cash per Share |
0.00 | 0.00 | 44.96 | 35.14 | |
Shareholders Equity per Share |
0.00 | 0.00 | 40.58 | 30.23 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 40.58 | 30.23 | |
Free Cash Flow |
(9.74) | — | (20.95) | (23.23) | |
Working Capital |
— | 123.35 | 103.55 | 82.35 | |
Capital Expenditures |
(0.59) | — | (0.01) | 0.00 | |
Net Current Asset Value |
— | 100.95 | 81.02 | 58.88 | |
| Other line items | |||||
Quick Ratio |
— | 8.83 | 7.17 | 5.12 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
(3.80) | — | (8.12) | (8.56) | |
Capex per Share |
(0.25) | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 30 Sep 2026